This therapy, along with the direct induction of cell death, abolishes the release of exosomes with pro-metastatic activity from breast cancer cells, decreasing the amount of proteins in the exosome cargo which can participate in the metastatic cascade such as Lactadherin and VE-cadherin. Here, MFGE8 is linked to breast carcinoma.